Literature DB >> 9632086

Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children.

L M Pachman1, J R Hayford, A Chung, C A Daugherty, M A Pallansch, C W Fink, H L Gewanter, R Jerath, B A Lang, J Sinacore, I S Szer, A R Dyer, M C Hochberg.   

Abstract

OBJECTIVE: To evaluate demographic and clinical characteristics, duration of time between disease onset (date of first rash and/or weakness), and diagnosis/therapy, as well as socioeconomic status, of children with newly diagnosed juvenile dermatomyositis (JDM).
METHODS: Structured telephone interview of families of a cohort of 79 children with JDM: interval between onset of symptoms to diagnosis, median of 3 months (range 0.5-20.0).
RESULTS: At diagnosis, all the children had rash (100%) and proximal muscle weakness (100%); 58 (73%) had muscle pain; 51 (65%) fever; 35 (44%) dysphagia; 34 (43%) hoarseness; 29 (37%) abdominal pain; 28 (35%) arthritis; 18 (23%) calcinosis, and 10 (13%) melena. Muscle derived enzymes were normal in 10% of the children. Of the 43 children who had an electromyogram (EMG), 8 (19%) had normal results. Fifty-one children had a muscle biopsy; the results were normal/nondiagnostic in 10 (20%). Median time from disease onset to diagnosis was different between racial groups: Caucasians (n=59) 2.0 months: for minorities (n=20), 6.5 months, (p=0.0008). The median time from disease onset to therapy was: Caucasians. 3.0 months; minorities, 7.2 months (p=0.002). Report of calcinosis was associated with increased time to diagnosis and therapy (p=0.04). In the 33 children whose first symptom occurred in June-September, rash preceded or accompanied onset of muscle weakness in 83% (n=27). Ninety-one percent of the children were given steroid therapy and 9% received methotrexate as well.
CONCLUSION: The results of an undirected site for muscle biopsy or EMG may not be diagnostic. Minority children had a longer interval between first JDM symptom and diagnosis/therapy than Caucasian children. Delay in diagnosis/therapy was associated with calcinosis.

Entities:  

Mesh:

Year:  1998        PMID: 9632086

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  32 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

2.  Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.

Authors:  J Tiao; R Feng; E M Berger; J F Brandsema; C C Coughlin; N Khan; E A Kichula; M A Lerman; S Lvovich; P J McMahon; L G Rider; A I Rubin; L V Scalzi; D M Smith; A J Taxter; J R Treat; R P Williams; S W Yum; J Okawa; V P Werth
Journal:  Br J Dermatol       Date:  2017-07-31       Impact factor: 9.302

Review 3.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

4.  Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.

Authors:  Luciena Cegatto Martins Ortigosa; Vitor Manuel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

5.  Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.

Authors:  Takayuki Kishi; William Warren-Hicks; Nastaran Bayat; Ira N Targoff; Adam M Huber; Michael M Ward; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

Review 6.  Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies.

Authors:  Chester V Oddis
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

7.  Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis.

Authors:  Jared Martillotti; Douglas Moote; Lawrence Zemel
Journal:  Pediatr Radiol       Date:  2013-07-10

8.  A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies.

Authors:  Neil Martin; Petra Krol; Sally Smith; Kevin Murray; Clarissa A Pilkington; Joyce E Davidson; Lucy R Wedderburn
Journal:  Rheumatology (Oxford)       Date:  2010-09-07       Impact factor: 7.580

9.  Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome.

Authors:  K Mizuno; A Yachie; S Nagaoki; H Wada; K Okada; M Kawachi; T Toma; A Konno; K Ohta; Y Kasahara; S Koizumi
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

10.  The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis.

Authors:  Roopa Seshadri; Brian M Feldman; Norman Ilowite; Gail Cawkwell; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.